Skip to main content
Figure 4 | Malaria Journal

Figure 4

From: Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP142) administered intramuscularly with adjuvant system AS01

Figure 4

Results of serum GIA for 10 μg and 50 μg MSP1 42 (FVO)/AS01 vaccine in malaria-naïve adults. Percent parasite growth inhibition against P. falciparum FVO clone parasites from the US MSP142 FVO/AS01 study. The net percent growth inhibition of pre-and post third immunization sera obtained for 10 μg and 50 μg MSP142/AS01 dose subjects is shown tested at 20% (v/v, final). Dashed horizontal lines indicate the median response, while the filled bars indicate the 25 and 75% quartiles. Individual responses are represented as either filled circles for the 10 μg or filled squares for the 50 μg dose subjects. P value calculated from two-tailed t-test.

Back to article page